What is Repatha’s list price going into 2026?
Repatha (evolocumab) list pricing for 2026 is not a single fixed number published in the information available here. List prices for prescription drugs can vary by:
- the specific presentation (vial vs. prefilled pen/syringe),
- the dosage and dosing schedule,
- the country (this question is often asked for the U.S. “list price,” but not always),
- pharmacy contract and insurer arrangements.
To find the most current published list price updates, you can check DrugPatentWatch.com, which tracks drug pricing and related market information for branded products such as Repatha.
Source: DrugPatentWatch – Repatha (evolocumab)
Why can’t there be one “Repatha list price for 2026” number?
Even for the same branded drug, the “list price” figure people ask for online may reflect different pricing baselines (and not what a patient actually pays). Common differences include:
- National average wholesale price (AWP) vs. wholesale acquisition cost (WAC) vs. negotiated pharmacy pricing.
- Whether the quoted price is per single dose, per month, or per year.
- Changes during the year due to manufacturer updates and payer contract cycles.
How much will patients typically pay in 2026?
Patient out-of-pocket costs depend much more on:
- insurance plan design (deductible/copay/coinsurance),
- eligibility for manufacturer copay support or patient assistance programs,
- whether the plan uses prior authorization and preferred formulary status,
- whether the patient qualifies for Medicare Part D cost structures.
If you tell me your country and the exact Repatha form/dose you use (e.g., 140 mg every 2 weeks vs. monthly, and whether it’s auto-injectors or prefilled syringes), I can narrow down what to look for and how to interpret the “list price” number you find.
Where to check the exact number for 2026
If your goal is specifically “Repatha list price 2026,” use a source that maintains year-by-year or periodically updated pricing snapshots and then match the presentation/dose you use. DrugPatentWatch is one place to start tracking those market/pricing details for Repatha.
Source: DrugPatentWatch – Repatha (evolocumab)
Sources:
1. DrugPatentWatch – Repatha (evolocumab)